Evidence map›Paper›PMID 42085155›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

ATP2B1 expression identifies human hematopoietic stem cells with superior repopulation and self-renewal.

Angelica Varesi, Murtaza S Nagree, Isabella Di Biasio, Andy G X Zeng, Sayyam Shah, Michael Zhang, Hyerin Kim, Alex Murison, Rohail Badami, Olga Gan and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. ATP2B1 expression identifies human hematopoietic stem cells with superior repopulation and self-renewal.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Angelica Varesi *Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
Murtaza S Nagree *Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Isabella Di BiasioPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Andy G X ZengDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
Sayyam ShahPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Michael ZhangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Hyerin KimPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Alex MurisonPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Rohail BadamiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Olga GanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Liqing JinPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Jessica McLeodPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Sheela A AbrahamDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
Mark D MindenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.ORCID 0000-0002-9089-8816
Andrea ArrudaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Igor Novitzky-BassoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Jonas MattssonPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
John E DickDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0002-9527-8317
Stephanie Z XiePrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.

Funding

Boehringer Ingelheim Fonds (BIF) Phd ScholarshipCanadian Cancer Society (CCS) 703212CIHR | Clinical Trials Fund, Canadian Institutes of Health Research (CTF) 543470 518950 507100 375173International Development Research Centre (IDRC) 364290Leukemia and Lymphoma Society (LLS) SCOR7039-25Princess Margaret Cancer Foundation (PMCF) Princess Margaret Postdoctoral Research AwardTerry Fox Research Institute (TFRI) PPG1106University of Toronto (UofT) PhD Scholarship
6 · The paper itself

Abstract

Long-term hematopoietic stem cells (LT-HSC) maintain lifelong hematopoiesis while preserving the stem cell compartment through self-renewal. The human LT-HSC compartment is molecularly and functionally heterogeneous and also varies across ontogeny. Dissecting the molecular basis for this variation is impeded by the paucity of immunophenotypic markers to resolve LT-HSC heterogeneity. Here, we identified ATPase plasma membrane calcium transporting 1 (ATP2B1/PMCA1) as a cell surface marker that is heterogeneously expressed by CD49f

Indexed as

Cell Self RenewalHematopoietic Stem CellsAnimalsFetal BloodHematopoiesisHumansMicecalciumhematopoietic stem celllysosome

Identifiers

PMID42085155
PMCPMC13167729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.